Microbiome-Targeting Therapeutics in Infectious Diseases - Thematic Research

Microbiome-targeting drugs aim to alter the microbial composition of the gut through the administration of live microbes with the intention of regulating the human microbiome composition in a beneficial way that may effectively treat a wide variety of infectious diseases (ID) ranging from cancer to psychiatric disorders, and even COVID-19.

There are currently 23 drugs in clinical development that target the microbiome for ID indications in the 7MM. Ten out of the 23 drugs (43%) are in in clinical development for Clostridioides difficile infections (CDI).

Currently, only one successful microbiome-based intervention, fecal microbiota transplantation (FMT), is used in clinical practice to treat CDI.

Rebiotix Inc currently holds the most potential in the microbiome space for infectious diseases, with two drug candidates under development across 4 different indications.

With most of the pipeline dominated by gastrointestinal (GI) tract infections, other indications remain a largely untapped market in the microbiome space, leaving ample opportunities for companies to invest in this novel therapeutic area.

Scope

Overview of microbiome-targeting drugs for infectious diseases including classification of therapy and technologies, regulatory and market access details, product & company profiles.
Quotes from US based key opinion leaders (KOLs).
Key topics covered for microbiome-targeting drugs for infectious diseases in the 7MM include trends, value chain, pipeline and market analysis, opportunities, challenges, and unmet needs.
Pipeline analysis: emerging novel trends under development, and analysis of the most promising late-stage microbiome-targeting pipeline drugs in pre-registration and Phase III of clinical development.
Analysis of the key dynamics of the microbiome-targeting drugs market in ID. Insightful review of the key industry drivers and challenges. Deals and R&D strategies covered in detail to highlight potential business opportunities.

Reasons to Buy

• What impact will late-stage pipeline agents have on the market? Which class of IO drugs will have the highest peak sales, and why?
• What are the current unmet needs and which pipeline drugs or strategies are positioned to counter these unmet needs? What are the opportunities for R&D in the microbiome-targeting in ID space?
• How is the field of microbiome-targeting therapies in ID going to move forward? Which indications are the most promising for combination therapy?
• What is the regulatory landscape for live biotherapeutic products (LBP) in the US and 5EU?
• What is the current and future outlook for microbiome-targeting therapeutics according to KOLs?